Asunaprevir
- Generic Name
- Asunaprevir
- Drug Type
- Small Molecule
- Chemical Formula
- C35H46ClN5O9S
- CAS Number
- 630420-16-5
- Unique Ingredient Identifier
- S9X0KRJ00S
- Background
Asunaprevir, also named BMS-650032, is a potent hepatitis C virus (HCV) NS3 protease inhibitor. It has been shown to have a very high efficacy in dual-combination regimens with daclatasvir in patients chronically infected with HCV genotype 1b. It was developed by Bristol-Myers Squibb Canada and approved by Health Canada on April 22, 2016. The commercialization of asunaprevir was cancelled one year later on October 16, 2017.
- Indication
Asunaprevir is indicated in combination with other agents for the treatment of chronic hepatitis C in adult patients with hepatitis C virus genotypes 1 or 4 and compensated liver cirrhosis.
Hepatitis C is a liver disease caused by the hepatitis C virus. The chronic state of this condition accounts for 60-80% of the cases from which the risk of cirrhosis of the liver within 20 years is of around 15-30%. The genotype 1 is the most common type of hepatitis C in the United States and the most difficult to treat.
- Associated Conditions
- Chronic Hepatitis C Genotype 1, Genotype 4 Chronic Hepatitis C
Study of BMS-650032 With Peginterferon Alfa-2a Plus Ribavirin
- Conditions
- Hepatitis C Virus
- Interventions
- First Posted Date
- 2009-12-11
- Last Posted Date
- 2015-10-09
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 285
- Registration Number
- NCT01030432
- Locations
- 🇺🇸
Umass Memorial Medical Center, Worcester, Massachusetts, United States
🇺🇸Hospital Of The University Of Pennsylvania, Philadelphia, Pennsylvania, United States
🇺🇸Alabama Liver & Digestive Specialists (Alds), Montgomery, Alabama, United States
Hepatic Impaired Subjects Compared to Healthy Subjects Receiving Multi-dose BMS-650032
- First Posted Date
- 2009-11-25
- Last Posted Date
- 2011-10-26
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 28
- Registration Number
- NCT01019070
- Locations
- 🇺🇸
Advanced Clinical Res Inst, Anaheim, California, United States
🇺🇸Orlando Clinical Research Center, Orlando, Florida, United States
Study to Determine the Effectiveness of Antiviral Combination Therapy to Treat Hepatitis C Virus (HCV) Infected Patients Who Have Previously Failed Standard of Care
- Conditions
- Chronic Hepatitis C
- Interventions
- First Posted Date
- 2009-11-13
- Last Posted Date
- 2015-10-09
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 215
- Registration Number
- NCT01012895
- Locations
- 🇺🇸
Advanced Clinical Research Institute, Anaheim, California, United States
🇺🇸Mercy Medical Center, Baltimore, Maryland, United States
🇺🇸Carolinas Center For Liver Disease, Statesville, North Carolina, United States
Drug-Drug Interaction Study in Healthy Subjects
- First Posted Date
- 2009-05-19
- Last Posted Date
- 2011-01-07
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 28
- Registration Number
- NCT00904059
- Locations
- 🇺🇸
Ppd Development, Lp, Austin, Texas, United States
A Multiple Ascending Dose Study of BMS-650032 in HCV Infected Subjects
- First Posted Date
- 2008-07-25
- Last Posted Date
- 2011-06-27
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 15
- Registration Number
- NCT00722358
- Locations
- 🇺🇸
Advanced Clinical Res Inst, Anaheim, California, United States
🇵🇷Local Institution, Santurce, Puerto Rico
🇺🇸Orlando Clinical Research Center, Orlando, Florida, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.